Phase II trial of methylglyoxal-bis (guanylhydrazone) (MGBG) in patients with refractory multiple myeloma: An eastern cooperative oncology group (ECOG) study

Jane N. Winter*, Paul S. Ritch, Steven T. Rosen, Martin M. Oken, Janet M. Wolter, Peter H. Wiernik, Michael J. O'connell

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Twenty patients with refractory multiple myeloma were treated with methylglyoxalbis(guanylhydrazone) (MGBG), an inhibitor of polyamine synthesis. MGBG 500 mg/m2 was administered on days 1 and 8, and then every 14 days. The dose was escalated to 600 mg/m2 on day 22, as tolerated. Of 14 evaluable patients, none met ECOG criteria for an objective response. The major toxicity was hematologic and related infections. MGBG demonstrated insufficient activity in the treatment of refractory multiple myeloma to warrant further study.

Original languageEnglish (US)
Pages (from-to)143-146
Number of pages4
JournalCancer Investigation
Volume8
Issue number2
DOIs
StatePublished - Jan 1 1990

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trial of methylglyoxal-bis (guanylhydrazone) (MGBG) in patients with refractory multiple myeloma: An eastern cooperative oncology group (ECOG) study'. Together they form a unique fingerprint.

Cite this